Navigation Links
Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
Date:11/25/2008

Results reveal most respondents against expanding statin use broadly in wake of AHA-presented data

LITTLE FALLS, N.J., Nov. 25 /PRNewswire/ -- JUPITER, a clinical trial suggesting rosuvastatin may lower the cardiovascular risk of healthy patients with elevated CRP, should not prompt universal statin use in older adults, according to a national poll directed at health professionals. Some 1,212 participants took part in the online poll conducted by medical news site MedPage Today LLC (www.MedPageToday.com).

(Photo: http://www.newscom.com/cgi-bin/prnh/20081125/NY48420 )

While the news coming out of the American Heart Association (AHA) Scientific Sessions on JUPITER was dramatic, respondents voted 60% to 40% against automatically prescribing statins in patients 60+ without elevated cholesterol.

"Our poll shows that healthcare professionals may not be so quick to change their Crestor or statin prescribing habits based on the results presented at AHA," said Robert Stern, President and CEO of MedPage Today. "The JUPITER results have created a debate between clinical data and the implications for real-world medical practice."

Whether the indication for Crestor should be expanded dramatically to include healthy patients became a major question after the JUPITER findings were presented at AHA and then published online in the New England Journal of Medicine.

In the clinical trial, 20 mg of rosuvastatin (Crestor) taken daily for just under two years reduced median LDL cholesterol to 55 mg/dL, down from a median of 108 mg/dL, and median hs-CRP (high-sensitivity C-reactive protein), a test measuring inflammation, by 37%. The corresponding reduction in the rate of heart attack, stroke, bypass surgery, or cardiovascular death was 44%.

MedPage Today poll participants registered mixed views as to the best preventive cardiovascular strategy, with most alternating between lifestyle changes and drug therapy.

Among the majority of those voting against lifelong drug therapy was one M.D., who commented, "The American people want the magic bullet that will allow them to continue their unhealthful lifestyles when they should lower their BMI to between 25 and 22, restrict caloric intake and [increase] exercise. What are the costs? Low."

The same physician lamented that funding more sound research into the biological origins of inflammation with the potential of devising activity and dietary strategies to prevent type II diabetes and cardiovascular disease is neither commercially viable for pharmaceutical corporations nor sufficiently funded by NIH and is thus "not likely to happen."

A second M.D., wary of statins, objected to placing people on medications who ostensibly don't need them. "Statins have side effects such as myopathy and ED with decreased libido in men and women," he observed. "Recently they have been associated with cognitive impairment and possible early development of Alzheimer's."

A third agreed, saying, "The side effects and potential for serious problems [with statins] outweighs the benefit. Muscle weakness is common, and often does not go away until months after stopping. Don't do it."

Statins, like any other drug, have side effects, "but research and time have shown their efficacy in lowering cardiovascular events," countered a general practitioner. Speaking for the minority of those who favor statins among the healthy elderly, he commented, "As family physicians, we are intended to [practice] preventive medicine." The combination of LDL <130 and CRP >2 should be "the golden key" for receiving treatment.

The JUPITER results, the G.P. continued, speak for themselves. "Billions of dollars will be saved," with fewer cardiovascular events, hospital days and engagement in rehab programs. "In practice, altering patient habits is not easy, and even when [patients] achieve the goal, how long will it be maintained? I inform the patient and let him decide."

MedPage Today polls are not scientific samplings of reader opinion; they are, rather, a snapshot of current thinking among the healthcare community. Totals may not add to 100% due to rounding and sample size.

About MedPage Today

MedPage Today is the only service for physicians that provides a clinical perspective on the breaking medical news that patients are reading. Co-developed by MedPage Today and The University of Pennsylvania School of Medicine, Office of Continuing Medical Education, each article alerts clinicians to peer-reviewed, breaking medical news, with summaries and actionable information enabling them to better understand the implications.

Physicians and other healthcare professionals may also receive Continuing Medical Education (CME) credits at no cost by completing these educational programs. CME is required of physicians in approximately 30 states, and utilization of electronic CME is growing at an estimated 80% annual rate.

MedPage Today received a Platinum honor in the 2008 eHealthcare Leadership Awards, the largest Web-oriented awards program focused exclusively on healthcare. MedPage Today bested more than 17 category entrants--out of a total field of some 1,100 entrants--to win for Best Health/Healthcare Content--Physician/Clinician-Focused Site.


'/>"/>
SOURCE MedPage Today, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
2. Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged
3. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
4. NJ-Based Surgeon Helps Pioneer Dramatic Advance in Treating Damaged Discs
5. Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation
6. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
7. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
8. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
9. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
10. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... YORK , Feb. 22, 2017 This report ... Thousand. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 ... these markets. Market data and analytics are derived from primary ...
(Date:2/23/2017)... Feb. 22, 2017 Medical Imaging ... imaging is performed to reveal the internal structures hidden ... the medical condition. It plays a vital role not ... as it is taken into consideration during the follow-up ... X-rays, SPECT/PET, ultrasound, CT, and MRI. For the diagnosis ...
(Date:2/23/2017)... 22, 2017 Summary Provides ... deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605669-summary/view-report.html Description The Global Non-Hodgkin ... provides understanding and access to partnering deals and ... companies. - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society demands ... the sharpest brain. , Power On, a mental performance enhancer from Modus Nutrition, ... brain. Each capsule contains Cognizin® Citicoline, a branded form of the brain health ...
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, the leading ... of hospitals, health information exchanges, physicians and patients, announced today that SES Direct ... Edition Health IT Module Certification via Drummond Group LLC, an Authorized Certification Body ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World ... TV host Tom Seay and his production crew. Tom Seay’s program “Best of ... the world. Saddle Sidekicks will be featured on April 6, 2017. After the ...
(Date:2/22/2017)... ... , ... ANGLESTRONG , the new recovery management app with multiple innovative ... Store and Google Play . Florida-based Sober Network, Inc., the premier provider ... with Angle to build ANGLESTRONG. The new recovery management app is a passion project ...
Breaking Medicine News(10 mins):